Technical Analysis for CHRO - Chromocell Therapeutics Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.32 | -2.93% | -0.04 |
CHRO closed down 2.93 percent on Friday, June 28, 2024, on 12 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -2.93% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| 20 DMA Support | Bullish | -8.45% | |
| Crossed Above 20 DMA | Bullish | -12.00% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
| Rose Above Previous Day's High | 2 days ago |
| 20 DMA Resistance | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound is CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as for the treatment of eye pain and neuropathic pain. The company was founded in 2002 and is based in Freehold, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Neuropathic Pain Erythromelalgia Sodium Channel Blockers
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Neuropathic Pain Erythromelalgia Sodium Channel Blockers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.0 |
| 52 Week Low | 1.22 |
| Average Volume | 17,404 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 1.57 |
| 20-Day Moving Average | 1.38 |
| 10-Day Moving Average | 1.38 |
| Average True Range | 0.17 |
| RSI (14) | 43.82 |
| ADX | 19.88 |
| +DI | 23.92 |
| -DI | 14.90 |
| Chandelier Exit (Long, 3 ATRs) | 1.23 |
| Chandelier Exit (Short, 3 ATRs) | 1.78 |
| Upper Bollinger Bands | 1.55 |
| Lower Bollinger Band | 1.22 |
| Percent B (%b) | 0.31 |
| BandWidth | 23.80 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.10 |
| MACD Histogram | 0.0173 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.32 | ||||
| Resistance 3 (R3) | 1.32 | 1.32 | 1.32 | ||
| Resistance 2 (R2) | 1.32 | 1.32 | 1.32 | 1.32 | |
| Resistance 1 (R1) | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 |
| Pivot Point | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 |
| Support 1 (S1) | 1.32 | 1.32 | 1.32 | 1.32 | 1.32 |
| Support 2 (S2) | 1.32 | 1.32 | 1.32 | 1.32 | |
| Support 3 (S3) | 1.32 | 1.32 | 1.32 | ||
| Support 4 (S4) | 1.32 |
